Cancer Treatment

Precision oncology gains ground as India clears targeted cancer therapies

A string of CDSCO approvals and reviews is accelerating India's move to immunotherapies, ADCs and targeted drugs, widening options in major cancers and boosting competition

Scientists edge closer to a universal cancer vaccine using nanoparticles

What if a single vaccine platform could train the immune system to prevent multiple cancers? A new nanoparti

French drugmaker Servier sharpens India strategy, eyes ₹1,000 cr revenue

Servier is stepping up its India push to bring first-in-class and precision medicines, expand global clinical research participation and use India for manufacturing and GCC services

HIV-free for seven years after cancer treatment, and doctors are amazed

A man treated for blood cancer has stayed HIV-free for seven years after a stem-cell transplant, even without the CCR5 mutation once seen as essential, shifting cure research

Cancer crisis intensifies globally, hitting low-resource countries hardest

Once seen as a disease of the wealthy, cancer now affects all regions, with a growing share of cases and deaths occurring in low- and middle-income countries

Datanomics: One in every 74 Indians at lifetime risk of lung cancer

Cancers of the respiratory system ranked fifth in India in 2022, with 1,43,062 reported cases. Digestive system cancers and breast cancer remained the top sites.

mRNA Covid shots could make cancer immunotherapy more effective, says study

Scientists have found that Covid-19 mRNA vaccines could enhance immune responses in cancer patients, potentially transforming how immunotherapy works

Most women in poorer countries miss early cancer detection, says Lancet

Women's cancers like breast, cervical, and ovarian are often detected late in poorer countries, sharply reducing survival chances, according to a global Lancet study

Study finds disparities in cancer research in India despite economic growth

India had a largely inconsistent growth in clinical research related to cancer since 2001, despite a strong economic growth, suggesting that development could be a contributing factor towards disparities among the low and middle-income countries in cancer research, according to a new study. Cancer cases and deaths are projected to surge in the coming decades with low and middle-income countries expected to bear a disproportionate burden. However, researchers, including those from the the Latin American Cooperative Oncology Group, said that clinical trials of cancer are disproportionally concentrated in high-income countries, even as previous evidence suggests an increase in trials among low and middle-income nations. The study, published in the journal 'CANCER', looked at disparities in the numbers and complexity of clinical trials over time and according to economic changes. Datasets from World Bank and ClinicalTrials.gov were analysed. Between 2001 and 2020, a total of 16,977 can

ICICI Bank, Tata Memorial to build ₹625 cr cancer facility in Navi Mumbai

The facility, funded through ICICI Bank's CSR arm, will house advanced radiation equipment and serve thousands of cancer patients annually at Tata Memorial's Navi Mumbai campus

New light-based therapy kills cancer without harming healthy cells

Scientists have developed a new light-based therapy using tin nanoflakes and LED light to kill up to 92% of cancer cells while sparing healthy tissue, offering hope for safer, home-based treatment

Glenmark Pharma signs $18 mn deal with Hengrui for cancer therapy drug

The agreement gives Glenmark exclusive rights to develop and commercialise cancer drug Trastuzumab Rezetecan outside China, the US, Europe, and other select markets

Can a simple sugar like glucose supercharge body's cancer-fighting T cells?

A new study reveals that glucose not only fuels energy but also equips immune T cells with tools to better organise and destroy cancer cells

This new compound may help treat aggressive triple-negative breast cancer

Researchers at IIT Guwahati and IASST have designed a novel compound showing promise against aggressive triple-negative breast cancer

GSK enters into oncology segment; launches therapies for gynae cancers

GlaxoSmithKline Pharmaceuticals on Monday said it has made a foray into the oncology segment, bringing precision therapies for gynaecological cancers. The company has introduced advanced therapies Jemperli (dostarlimab) and Zejula (niraparib) in the country. "These therapies address a critical unmet need in gynaecological cancers in India and represent meaningful progress in women's cancer care. With this launch, we are strengthening our long-term commitment to build the specialty medicine portfolio in India," GSK India MD Bhushan Akshikar said in a statement. Gynaecological cancers are among the most common cancers in women in India. By 2045, the incidence of endometrial and ovarian cancer in India is projected to increase by 78 per cent and 69 per cent, respectively. Endometrial cancer is a malignancy arising out of the endometrium, the inner lining of the uterus. Nearly a fourth of endometrial cancer patients in India are at an advanced stage where chemotherapy remains a standa

Could this tiny genetic mutation be making humans more prone to cancer?

A mutation in the immune protein FasL may make humans more vulnerable to solid tumours, but scientists say it could be fixed through combination immunotherapy

This is what 'magic mushrooms' do to cancer patients with depression

A new study finds that psilocybin, the hallucinogenic compound in magic mushrooms, can offer long-term relief from depression and anxiety in cancer patients

Glenmark set to launch blood cancer treatment drug Brukinsa in India

Glenmark will introduce Brukinsa, a BTK inhibitor developed by BeOne Medicines, in India after DCGI approval to treat five B-cell blood cancers with proven safety and efficacy

Dr Reddy's, Alvotech join hands to develop biosimilar for cancer treatment

Dr Reddy's Laboratories on Thursday said it has joined hands with global biotech firm Alvotech to co-develop and commercialise a biosimilar product for treating multiple types of cancer. The Hyderabad-based drug major has entered into a collaboration and license agreement to co-develop, manufacture and commercialize a biosimilar candidate to Keytruda (pembrolizumab) for global markets, Dr Reddy's Laboratories said in a statement. Keytruda (pembrolizumab) is indicated for the treatment of numerous cancer types. In 2024, worldwide sales of Keytruda were USD 29.5 billion. The collaboration combines Dr Reddy's and Alvotech's proven capabilities in biosimilars thereby speeding up the development process and extending the global reach for this biosimilar candidate, the company noted. Under the terms of the agreement, the parties will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities, it stated. Subject to certain ...

Joe Biden's prostate cancer: Risks, symptoms, treatment options explained

Joe Biden's metastatic or stage 4 prostate cancer diagnosis highlights common symptoms, risk factors, and treatment options men should know about